Lakeisha Mulugeta‐Gordon

Immune Checkpoint Inhibitors: Sculpting the Landscape of Endometrial Cancer Treatment

Background: Outcomes for advanced or recurrent endometrial cancer (EC) remain poor, with historically limited systemic options beyond platinum-based chemotherapy. EC is uniquely immunotherapy-amenable among solid tumors: it harbors the highest prevalence of mismatch repair defici...